Clinical Microbiology and Infection最新文献

{"title":"The importance of long-term follow-up data in Chagas disease: New challenges for old paradigms.","authors":"Clara Crespillo-Andújar, José A Pérez-Molina","doi":"10.1016/j.cmi.2025.06.024","DOIUrl":"https://doi.org/10.1016/j.cmi.2025.06.024","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'Association between pertactin-producing Bordetella pertussis and fulminant pertussis in infants' - Author's reply.","authors":"Pauline Leroux, Valérie Bouchez, Carla Rodrigues, Jérémie F Cohen, Sylvain Brisse, Julie Toubiana","doi":"10.1016/j.cmi.2025.06.020","DOIUrl":"https://doi.org/10.1016/j.cmi.2025.06.020","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to 'Kinetics of the Alethia® Malaria LAMP positivity during Post-treatment Follow-up of Patients with imported Malaria' [Clinical Microbiology and Infection journal. Volume 31, Issue 6, June 2025, Pages 1069-1070].","authors":"Emilie Sitterlé, Céleste Lambert, Anthony Marteau, Sophie Brun, Eric Dannaoui, Marie-Elisabeth Bougnoux","doi":"10.1016/j.cmi.2025.06.027","DOIUrl":"https://doi.org/10.1016/j.cmi.2025.06.027","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thank you to our peer-reviewers: CMI 2024.","authors":"Julia Friedman, Leonard Leibovici","doi":"10.1016/j.cmi.2025.06.028","DOIUrl":"https://doi.org/10.1016/j.cmi.2025.06.028","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of COVID-19 in Immunocompromised Patients: An ESCMID Consensus Document.","authors":"Michele Bartoletti, Ozlem Azap, Aleksandra Barac, Manel Ben Selma, Onder Ergonul, Effrossyni Gkrania-Klotsas, Paolo Antonio Grossi, Robert Krause, Blin Nagavci, José Ramón Paño-Pardo, Ligia Camera Pierrotti, Nicholas Power, Jesús Rodríguez-Baño, Marcella Sibani, Monica A Slavin, Balint Gergely Szabo, Beatrice Tazza, Nicole Ngai Yung Tsang, Sotirios Tsiodras, Ines Zollner-Schwetz, Roy F Chemaly","doi":"10.1016/j.cmi.2025.05.032","DOIUrl":"https://doi.org/10.1016/j.cmi.2025.05.032","url":null,"abstract":"<p><strong>Introduction: </strong>Data on treatment of COVID-19 in immunocompromised patients emerged recently ; however, published guidelines for management of COVID-19 in immunocompromised patients are lacking.</p><p><strong>Aim and methods: </strong>To develop consensus statements derived from evidence and expert opinion on management of COVID-19 in immunocompromised patients an expert panel was convened by ESCMID. The expert panel developed a list of questions which are of general interest for clinicians and readers with backgrounds in clinical microbiology and infectious diseases. Six questions were selected. For each question, systematic literature searches were undertaken. We considered most study types, including clinical trials, observational studies with or without a control group, systematic reviews, case series, and case reports. Detailed inclusion criteria were defined for each research question using the Population Intervention Comparison Outcome format. Immunocompromised patients included patients with 1) primary immune deficiencies; 2) active malignancy or malignancy diagnosed or received cancer therapies within 1 year of COVID-19 diagnosis, 3) HIV with a CD4+ T-lymphocyte count < 200 cells/mm3 or percentage < 14%; 4) receipt of solid organ transplant (SOT) within 1 year of COVID-19 diagnosis; 5) receipt of hematopoietic cell transplant (HCT) or chimeric antigen receptor T-cell therapy within 1 year of COVID-19 diagnosis; 6) receipt of systemic corticosteroid therapy with a dose of ≥ 20 mg prednisone or equivalent daily for ≥ 14 days or a cumulative dose of > 600 mg of prednisone; 7) receipt of biological immune modulators; or 8) receipt of disease-modifying antirheumatic drugs or other immunosuppressive drugs. The panel's consensus statements were based on evidence, supplemented by experience and expert opinion, especially in cases when evidence was limited or scarce. This document is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of tuberculosis disease among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biologics in Denmark: a nationwide cohort study.","authors":"Christian Kraef, Anne Ahrens Østergaard, Troels Lillebaek, Pernille Ravn, Andreas Fløe, Lone Larsen, Ada Colic, Inge Petersen, Isik Somuncu Johansen","doi":"10.1016/j.cmi.2025.06.017","DOIUrl":"https://doi.org/10.1016/j.cmi.2025.06.017","url":null,"abstract":"<p><strong>Objectives: </strong>This nationwide retrospective cohort study estimates TB disease risk in adults and children with inflammatory bowel disease (IBD) and inflammatory rheumatic disease (IRD) treated with immunosuppressive biologics in Denmark, including temporal trends and risk stratification by TB infection status and country of birth.</p><p><strong>Methods: </strong>Patients diagnosed with IBD or IRD between 1994 and 2018 were identified using the Danish National Patient Registry. Treatments with biologics and diagnoses of TB disease were determined through ICD-10 codes and microbiological records. Patient demographics, interferon-gamma release assay (IGRA) results, and drug use data were collected from national databases. Poisson regression was used to calculate TB incidence rates (IR) and assess associations with biologic treatment, IGRA-status, country of birth, age, and sex.</p><p><strong>Results: </strong>During 553,551 person-years of follow-up (PYFU), 117 patients with TB disease were identified, with 71 cases occurring in biologic-naïve patients and 46 in biologic treated individuals. The crude IR was 39.3/100,000 PY (95% CI 29.4-52.4) for biologic treated individuals, compared to 12.4/100,000 PY (95% CI 9.2-16.8) for naive patients, yielding an incidence rate ratio (IRR) of 3.2 (95%CI 2.0-4.9). The TB risk was higher in IGRA-positive patients (vs. negative, IRR 45.0, 95% CI 12.0-168.2) and those born in intermediate (vs. low incidence country, IRR 7.9, 95% CI 3.3-18.9) or high TB-incidence countries (vs. low incidence country, IRR 7.5, 95% CI 2.9-19.1).</p><p><strong>Conclusion: </strong>The elevated risk of TB disease in patients with IRD and IBD treated with biologics is strongly associated with IGRA positivity and country of birth. These findings highlight the importance of comprehensive baseline TB risk assessment, patient education in combination with personalized follow-up to guide preventive strategies in this population.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B' - Author's reply.","authors":"Xuejiao Liao, Yingying Su, Jun Zhang, Zheng Zhang","doi":"10.1016/j.cmi.2025.06.019","DOIUrl":"https://doi.org/10.1016/j.cmi.2025.06.019","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquisition and clearance of enteric pathogens in children under 5 years of age in Kigali and Musanze, Rwanda, 2022: A longitudinal cohort study.","authors":"Jean Bosco Munyemana, Jean Claude Kabayiza, Eric Seruyange, Staffan Nilsson, Maria E Andersson, Magnus Lindh","doi":"10.1016/j.cmi.2025.06.018","DOIUrl":"https://doi.org/10.1016/j.cmi.2025.06.018","url":null,"abstract":"<p><strong>Objectives: </strong>Reducing diarrhea and stunting due to enteric infections requires an understanding of pathogen acquisition and clearance. This longitudinal study analyzed the dynamics of enteric infections among children in two study sites in Rwanda in 2022.</p><p><strong>Methods: </strong>Children with diarrhea were enrolled at two study sites (60 at each site; mean age 18.7 [SE=1.11] months, 48% girls), one near the capital Kigali, and one in a northern rural district (Musanze). Rectal swab samples were collected at inclusion and monthly intervals during five months of follow-up, and additionally in case of diarrhea, and were analyzed by real-time PCR for a broad panel of diarrheagenic pathogens.</p><p><strong>Results: </strong>During follow-up, acquisition of bacteria was very common, corresponding to 1.86 (CI 1.52-2.23) new ETEC-eltB and 1.24 (CI 0.96-1.57) new Shigella/EIEC detections per year per child, and bacterial infections were significantly more common in Musanze (ratio 1.24, P=0.0001), but the acquired infections rarely caused diarrhea. Most viruses (78-100%) and bacteria (47-86%) were cleared before the next sampling time point. Diarrhea was significantly associated with rotavirus (OR 7.24, P<0.0001), despite a high rotavirus vaccination coverage, and with enterotoxigenic Escherichia coli (ETEC) -estA (OR 3.84, P<0.0001), ETEC-eltB (OR1.99, P=0.001), and norovirus genogroup II (OR=2.74, P=0.0004). Detection of Campylobacter at baseline and follow-up correlated (P=0.005), indicating maintained exposure.</p><p><strong>Conclusions: </strong>New enteric infections were very common, in particular in rural areas, but rarely caused diarrhea and most infections were effectively cleared. The findings show that heavy pathogen exposure rather than persistent infections explain the high prevalence of enteric infections among children in poor countries. Rotavirus remains a significant cause of diarrhea a decade after vaccine introduction, indicating that vaccination mainly protects against severe symptoms and less against infection with no or moderate symptoms.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remdesivir and risk of multi-systemic long-term sequelae following COVID-19 hospitalisation.","authors":"Liang En Wee, Jue Tao Lim, An Ting Tay, Calvin J Chiew, Barnaby Edward Young, Shawn Vasoo, Huei Xin Lou, David Chien Lye, Kelvin Bryan Tan","doi":"10.1016/j.cmi.2025.06.016","DOIUrl":"10.1016/j.cmi.2025.06.016","url":null,"abstract":"<p><strong>Objectives: </strong>Significant heterogeneity has been reported in cohort studies evaluating the impact of antiviral treatment on long-term sequelae following COVID-19 hospitalisation. We evaluated the impact of intravenous (IV) remdesivir on risk of subsequent long-term cardiovascular/neurological/respiratory/autoimmune diagnoses and persistent symptoms.</p><p><strong>Methods: </strong>National COVID-19 registries and healthcare claims databases were utilised to construct a retrospective population-based cohort enrolling all adult Singaporeans hospitalised for COVID-19 (1^st Sept 2021-31^st Jul 2023), who fulfilled criteria for IV remdesivir. The cohort was divided into remdesivir-treated and untreated groups, with between-group differences in baseline sociodemographic and clinical characteristics adjusted using overlap-weighting. Risks of long-term new-incident (31-300 days) diagnoses/symptoms across cardiovascular/neurological/respiratory/autoimmune systems were compared across untreated/treated groups via competing-risks-regression.</p><p><strong>Results: </strong>30,175 COVID-19 hospitalisations were included in the cohort for evaluating risk of long-term sequelae; 37.6% (11,353/30,175) received remdesivir. 88.9% of the cohort were fully-vaccinated, and 60.5% had received a booster dose; 77.4% were infected during Omicron. Risk of long-term new-onset diagnoses across cardiovascular, neurological, respiratory and autoimmune systems (any long-term diagnosis, adjusted-hazards-ratio, aHR=1.08[95%CI=0.97-1.20]) up to 300 days post-COVID-19-hospitalisation was not significantly different in the remdesivir-treated group, versus untreated individuals, across age and vaccination subgroups. Similarly, no significant difference in the incidence of long-term symptom persistence at 300 days post-COVID-19-hospitalisation was observed in the remdesivir-treated group, versus untreated individuals.</p><p><strong>Conclusion: </strong>Receipt of remdesivir did not significantly reduce risk of long-term multi-systemic sequelae or long-term symptoms in a boosted cohort of adult Singaporeans hospitalised with COVID-19.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and strategies in the treatment of periprosthetic joint infection caused by multidrug-resistant Gram-negative bacteria: a narrative review.","authors":"Joan Gómez-Junyent, Jaime Lora-Tamayo, Luisa Sorlí, Oscar Murillo","doi":"10.1016/j.cmi.2025.06.015","DOIUrl":"10.1016/j.cmi.2025.06.015","url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant Gram-negative bacteria (MDR-GNB) are an increasing cause of periprosthetic joint infection (PJI), limit the available antibiotic options and affect patient outcomes.</p><p><strong>Objectives: </strong>We reviewed the therapeutic strategies for managing PJI caused by MDR-GNB, including surgical and antibiotic options.</p><p><strong>Sources: </strong>We performed a search regarding PJI caused by MDR-GNB without date restrictions, including experimental and clinical studies.</p><p><strong>Content: </strong>Surgery plays a central role in the therapeutic approach to PJI caused by MDR-GNB. Although prosthesis removal provides higher cure rates than debridement, antibiotics and implant retention (DAIR), also allowing the addition of local active antibiotics, the surgical risks should be considered when using it as an elective procedure in acute PJI. DAIR may be a valid option for selected patients, but this is the most challenging scenario. The selection of antibiotic treatment is limited by antimicrobial susceptibility, with fluoroquinolone resistance being a particular problem, and mostly requires long-term intravenous therapy. Beta-lactams represent the first-line therapy, ideally in combination in cases managed with DAIR, and should be used at high doses and in extended/continuous infusion to optimize their anti-biofilm efficacy. Colistin in combination with beta-lactams is the therapy with the most substantial clinical experience, although clinicians may also consider the use of trimethoprim-sulfamethoxazole, fosfomycin or tigecycline depending on their susceptibility. Outpatient parenteral antibiotic therapy is a valid strategy to minimize lengthy hospitalisations while ensuring good outcomes.</p><p><strong>Implications: </strong>The management of PJI caused by MDR-GNB is complex. Due to limited available evidence, an individualized approach is needed regarding the type of surgery and antimicrobial therapy, balancing the clinical effectiveness and toxicity risks. Currently, intravenous beta-lactams are commonly the first-line therapy, which should be administered for long periods, mainly in combination. The optimization of the anti-biofilm effects of therapy and drug monitoring during the treatment is advisable.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}